Classification and selection of drugs for treating osteoporosis

doi:10.3877/cma.j.issn.2096-0263.2019.05.010

Abstract

Abstract:

Osteoporosis is the main disease affecting the health of the elderly. Its disability and mortality are high, which seriously affects the quality of life and life of patients, and brings huge human and economic burden to families and society. With the intensification of the population aging process, osteoporosis has become more and more concerned by the society, and anti-osteoporosis drug research has become a hot spot. Traditional classification methods are classified according to the mechanism of action of drugs, and a wide variety of drugs make clinical drug selection difficult. In the course of treatment, both the mechanism of action of the drug and the individual function of the patient should be considered, and the principle of drug selection should be reclassified.

Key words: Osteoporosis, Drug therapy, Bone density

Jianhua Wang. Classification and selection of drugs for treating osteoporosis[J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2019, 05(05): 297-300.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlngkykfdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-0263.2019.05.010

https://zhlngkykfdzzz.cma-cmc.com.cn/EN/Y2019/V05/I05/297

References 36

[1]	中国健康促进基金会骨质疏松防治中国白皮书编委会.骨质疏松症中国白皮书[J].中华健康管理学杂志, 2009, 3(3): 148-154.
[2]	Cosman F,De Beur SJ,Leboff MS, et al. Clinician's guide to prevention and treatment of osteoporosis [J]. Osteoporos Int, 2014, 25(10): 2359-2381.
[3]	Rivadeneira F,Mäkitie O. Osteoporosis and bone mass disorders:from genepathwaystotreatments [J]. Trends Endocrinol Metab, 2016, 27(5): 262-281.
[4]	Seeman E,Delmas PD. Bone quality-thematerial and structural basis of bone strength and fragility [J]. N Engl J Med, 2008, 26(1): 1-8.
[5]	Mafi Golchin M,Heidari L,Ghaderian SM, et al. Osteoporosis: a silent disease with complex genetic contribution [J]. J Genetics Genomics, 2016, 43(2): 49-61.
[6]	Lewiecki EM. New targetsforintervention in the treatment of postmenopausal osteoporosis [J]. Nat Rev Rheumatol, 2011, 7(11): 631-638.
[7]	Balk EM,Adam GP,Langberg VN, et al. International osteoporosis foundation Calcium steering committee [J]. Global dietary calcium intake among adults:a systematic review[J].Osteoporos Int, 2017, 28(12): 3315-3324.
[8]	NordinBE. Calcium and osteoporosis [J]. Nutrition, 1997, 13(7/8): 664-686.
[9]	Wu J,Xu L,Lv Y, et al. Quantitative analysis of efficacy and associated factors of calcium intake on bone mineral density in postmenopausal women [J]. Osteoporos Int, 2017, 28(6): 2003-2010.
[10]	中华医学会骨质疏松和骨矿盐疾病学会.原发性骨质疏松症诊疗指南(2017) [J].中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5): 413-444.
[11]	Dawson-Hughes B. What is the optimal dietary intake of vitamin D for reducing fracture risk? [J]. Calcif Tissue Int, 2013, 92(2):184-190.
[12]	Wahl DA,CooperC,EbelingPR, etal. A global representation of vitamin D status in healthy populations[J]. Arch Osteoporos, 2012, 7:155-172.
[13]	Li M,Lv F,Zhang Z, et al. Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density [J]. OsteoporosInt, 2016, 27(5): 1907-1916.
[14]	Holick MF. Vitamin D deficiency [J]. N Engl J Med, 2007, 357(3): 266-281.
[15]	Han SL,Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials [J]. Int J Clin Pract, 2012, 66(2): 199-209.
[16]	Carmel AS,Shieh A,Bang H, et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is≥33 ng/ml [J]. Osteoporos Int, 2012, 23(10): 2479-2487.
[17]	Peris P,Martínez-Ferrer A,Monegal A, et al.25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis[J].Bone, 2012, 51(1): 54-58.
[18]	陈志军,邱勇.雌激素对骨骼作用机制的研究进展[J].中华创伤杂志, 2008, 24(4): 314-317.
[19]	WeitzmannMN,PacificiR. Estrogen deficiency and bone loss:aninflammatorytale [J]. JClinInvest, 2006, 116(5): 118.
[20]	易剑华,蒋志平.骨质疏松症的药物治疗进展[J].现代医院,2006,6(11): 55-56.
[21]	林华,包丽华,韩祖斌,等.降钙素治疗骨质疏松症骨质量病变的研究[J].中华骨科杂志, 2001, 21(9): 6-8.
[22]	李晓林,罗新乐,余楠生,等.鲑鱼降钙素对骨质疏松大鼠骨折愈合的影响[J].中国骨质疏松杂志, 2003, 9(2): 17-19, 53.
[23]	Lj X,Luo X,Yu N, et al. Effects of salmon calcitonin onfracture healing in ovariectomizedrats [J]. Saudi Med J, 2007, 28(1): 60-64.
[24]	Canalis E,Giustina A,Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis [J]. N Engl J Med, 2007, 357(9): 905-916.
[25]	Bukata SV,Puzas JE. Orthopedic uses of teriparatide [J]. CurrOsteoporos Rep, 2010, 8(1): 28-33.
[26]	NakajimaA,ShimojiN,ShiomiK,et a1.Mechanisms for theenhancement of fracture healing in ratstreated with intermittentlow-dosehumanparathyroidhormone(1-34)[J].JBone MinerRes,2002,17(11):2038-2047．
[27]	Taranta A,Brama M,Teti A, et al. The selective estrogenreceptormodulatorraloxifeneregulates osteoclast and osteoblast activity in vitro [J]. Bone, 2002, 30(2): 368-376.
[28]	刘立朝,樊继援.雷洛昔芬对去卵巢大鼠骨组织雌激素受体α表达水平的调节[J].中华骨质疏松和骨矿盐疾病杂志, 2013, 6(2): 161-164.
[29]	廖晖,李锋.二磷酸盐抑制骨吸收作用机制的研究现状[J].生物骨科材料与临床研究, 2004, 1(2): 20-24.
[30]	Abe Y,Iba K,Sasaki K, et al. Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice [J]. J Bone Miner Metab, 2015, 33(2): 125-134.
[31]	FleischH.Canbisphosphonates be given to patients with fractures? [J].JBoneMinerRes, 2001, 16(3): 437-440.
[32]	Schilcher J,Koeppen V,Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use [J]. N Engl J Med, 2014, 371(10): 974-976.
[33]	Moen MD,Keam SJ. Denosumab: areview of itsuse in thetreatment of postmenopausalosteoporosis[J].DrugsAging, 2011, 28(1): 63-82.
[34]	Mcclung MR,Boonen ST，Rring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis[J]. Journal of bone and mineral research，2012, 27(1):211-218.
[35]	Nikhil K,Sharan S,Roy P. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells[J]. Pharmacological Reports, 2015, 67(6):1264-1272.
[36]	Ke HZ,Richards WG,Li XD, et al. Sclerostin and dickkopf-1 as therapeutic targets in bone diseases [J]. Endocr Rev, 2012, 33(5): 747-783.

Please choose a citation manager

Content to export